1-3 of 3
Samuel Yamshon
Close
Sort by
Journal Articles

Absolute Lymphocyte Count after BCMA CAR-T Therapy is a Predictor of Response and Outcomes in Relapsed Multiple Myeloma

Mateo Mejia Saldarriaga, Darren Pan, Caitlin Unkenholz, Tarek H Mouhieddine, Juan Esteban Velez-Hernandez, Katherine Engles, Joshua Alexander Fein, Jorge Monge, Cara A Rosenbaum, Roger Pearse, David S. Jayabalan, Christian A Gordillo, Hei Ton Chan, Samuel Yamshon, Santiago Thibaud, Markus Y Mapara, Giorgio GA Inghirami, Suzanne Lentzsch, Ran Reshef, Adriana Rossi, Samir Parekh, Sundar Jagannath, Shambavi Richard, Ruben Niesvizky, Mark Bustoros
Journal: Blood Advances
Blood Adv bloodadvances.2023012470.
https://doi.org/10.1182/bloodadvances.2023012470
Published: 2024
Includes: Supplemental data
Journal Articles

Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphoma

Clinical Trials & Observations
Samuel Yamshon, Gui Zhen Chen, Caitlin Gribbin, Paul Christos, Bijal Shah, Stephen J. Schuster, Sonali M. Smith, Jakub Svoboda, Richard R. Furman, John P. Leonard, Peter Martin, Jia Ruan
Journal: Blood Advances
Blood Adv (2023) 7 (21): 6579–6588.
https://doi.org/10.1182/bloodadvances.2023010606
Published: 2023
Journal Articles

Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: a systematic review and meta-analysis

Clinical Trials & Observations
Samuel Yamshon, Paul J. Christos, Michelle Demetres, Hoda Hammad, John P. Leonard, Jia Ruan
Journal: Blood Advances
Blood Adv (2018) 2 (12): 1429–1438.
https://doi.org/10.1182/bloodadvances.2018016683
Published: 2018
Includes: Supplemental data